VAN NOSTRAND ROBERT L 4
4 · Intra-Cellular Therapies, Inc. · Filed Jun 21, 2024
Insider Transaction Report
Form 4
VAN NOSTRAND ROBERT L
Director
Transactions
- Exercise/Conversion
Common Stock
2024-06-18$16.86/sh+20,000$337,200→ 29,690 total - Sale
Common Stock
2024-06-18$75.71/sh−8,891$673,138→ 20,799 total - Exercise/Conversion
Stock Option (right to buy)
2024-06-18−20,000→ 0 totalExercise: $16.86Exp: 2024-06-30→ Common Stock (20,000 underlying) - Sale
Common Stock
2024-06-18$76.07/sh−11,109$845,062→ 9,690 total
Footnotes (5)
- [F1]On June 18, 2024, the reporting person exercised options to purchase 20,000 shares of common stock that are expiring on June 30, 2024.
- [F2]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2024.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.01 to $76.00, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.01 to $76.09, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F5]This option was granted on June 30, 2014 and will expire on June 30, 2024. All shares underlying this option have vested.